A strong association between higher tumor PD-L1 expression and adverse clinical outcomes was reported in RCC patients receiving anti-VEGF targeting therapy [6], leading to a focus on PD-1/PD-L1 blockade as a possible strategy for antitumor immunotherapy in patients with advanced RCC [25]. Here, PDCD1 is linked to renal cell carcinoma.